This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Research by GlobalData (Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition) shows that containment facilities are in high demand as the use of cytotoxic drugs continues to grow. Adding to these factors is that oncology accounts for the majority of marketed, contained drugs. Containment challenges.
The download contains detailed information on the providers and their services and solutions, alongside contact details to aid your purchasing decision.
The document contains detailed information on the suppliers and their product offerings, alongside contact details to aid your purchasing or hiring decision. Quality in terms of number of defective items, packaging and labelling, quality management system certification, research, development, and innovation.
Pharmaceutical drug research and development (R&D) activities are capital-intensive, which makes the outsourcing of clinical dose manufacturing and marketing popular. The download contains detailed information on the providers and their services and solutions, alongside contact details to aid your purchasing or hiring decision.
The document contains detailed information on the suppliers and their products, alongside contact details to aid your purchasing or hiring decisions. The post Leading API chemical companies in contract marketing appeared first on Pharmaceutical Technology.
The information contained within the download document is intended for pharmaceutical manufacturers, wholesalers, retailers and distributors, pharmaceutical executives, medical representatives, businessdevelopment managers, retail salesmen, sales managers, pharmacy executives, and any other individual involved in pharmaceutical marketing.
The download contains detailed information on the providers and their services and solutions, alongside contact details to aid your purchasing or hiring decision. Contract marketing of commercial doses.
The list of pharmaceutical solid dose manufacturing companies includes providers of solid state and pre-formulation technologies, IND/NDA filing support, technologies for cGMP manufacturing of APIs and intermediates from lab to commercial scale, process optimisation, and designing and developing manufacturing processes.
A container closure system consists of all the packaging components that contain and protect a pharmaceutical product. Container Closure Systems. A container closure system protects the product from environmental conditions, safeguarding a product’s purity, strength, safety and efficacy.
The document contains detailed information on the suppliers and their product offerings, alongside contact details to aid your purchasing or hiring decision. The advancement in drug design has led to the development of new drug molecules in the form of API peptides and proteins. Technologies in the delivery of peptides and proteins.
Large medical and pharmaceutical companies are partnering with small compounding solution providers and research organisations and targeting major compounding pharmacies in regions such as the Asia Pacific to create a sustainable position in the compounding pharmacies market. Test method development.
The document contains detailed information on the suppliers and their product offerings, alongside contact details to aid your purchasing or hiring decision.
Komodo Health’s president and co-founder, Web Sun, tells us about his company’s new partnership with the Chan Zuckerberg Initiative (CZI) to improve early diagnosis and advance research of rare diseases by providing CZI’s Rare as One Network healthcare data and software. CZI has also partnered with large data collection agencies before.
Research also shows that embracing biosimilars and patient choice will lead to the competition needed to further increase access to both biosimilars and biologics for 1.2 The PDPRA is slated for Senate review in 2021; it is aimed at lowering the cost of drugs for patients and contains several provisions that would impact biosimilars.
MBA, as the Company’s Chief Business Officer following the retirement of Wenji Chen, PhD, MBA, from her position as Vice President of Corporate Development. Earlier in his career, he ran business-development functions at Amgen and Baxter. Cautionary Note on Forward-Looking Statements. Source link.
Lilly Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) related to expected dividend payments and potential share repurchases and reflects Lilly ‘s current beliefs and expectations.
“We knew we had the opportunity to create something special when we saw the positive response to our previous seasonal collaborations for Dunkin’-inspired beers,” said Brian Gilbert, vice president of retail businessdevelopment at Dunkin’, in a press release. percent between 2022 and 2030. ounce cans.
It’s clear that geography and culture impact the research methodologies one must use for effective KOL identification and mapping. It’s essential to add additional identification and mapping research modalities that are able to directly ascertain both the voice of the KOL and the voice of the HCP. BusinessDevelopment Account Manager.
The trial, conducted in collaboration with the Swiss Group for Clinical Cancer Research (SAKK), will assess the safety, tolerability and anti-tumor activity of IP-001 administered intratumorally following tumor ablation. Contact: Dr. Theresa Visarius
Vice President BusinessDevelopment, Immunophotonics, Inc.
In addition, LogicBio has a collaboration with Takeda to research and develop LB-301, an investigational therapy leveraging GeneRide for the treatment of the rare pediatric disease Crigler-Najjar syndrome. LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies.
The poster presentation, given by Johan Sandin , CSO at AlzeCure, presents how the mechanisms in the research platform Alzstatin work and shows that the target mechanism within the platform is suitable as a new treatment for Alzheimer’s disease.
STOCKHOLM , Nov.
About AlzeCure Pharma AB (publ).
George Yeh, President of TLC, commenced the conference and welcomed the company’s new Chief Business Officer, Mr. Tom Bliss. With experiences attained in licensing and businessdevelopment functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese.
About TLC. Source link.
is a research and development company that develops topical and transdermal consumer products including DermSafe, all made with patented Invisicare® skin delivery technology. Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release.
Barber is an associate professor of biology and director of the Office of Student Research. Her research focuses on determining the role costimulatory domains play in enhancing chimeric T-cell activity and the creation and testing of the chPD1 receptor as a therapy for multiple types of cancer. Dr. Barber is a tumor immunologist.
This businessdeveloped positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. Notes: The following tables contain the key data for the Bayer Group and its divisions for the first quarter of 2021.
The publication presents real-world evidence related to abuse, misuse and diversion of Xtampza ER assessed using Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS ® ) system data sources. This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
The information contained within the download document is intended for manufacturers, suppliers, distributors, pharmaceutical executives, medical representatives, distributors, pharmacists, businessdevelopment managers, retail salesmen, sales managers, product marketing managers, and any other individual involved in drug injectables marketing.
The document contains detailed information on the suppliers and their product offerings, alongside contact details to aid your purchasing decision. Role of freeze-drying systems in the pharmaceutical industry The pharmaceutical freeze-drying market is highly governed by stringent standards and laws.
Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent businessdevelopment. “We delivered strong performance this quarter, with volume-driven growth across our core business and most major geographies. on a non-GAAP basis.
Research and development expenses increased 90% to $2.5 Research and development expense. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document. billion in the quarter primarily due to $1.1
This trial, which is being coordinated by researchers at the University of Oxford , is in patients hospitalized with COVID-19 and will compare the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own. Corporate and BusinessDevelopment Update. Research and development (R&D). $.
20, 2020 /PRNewswire/ — Sartorius , a leading international partner of life science research and the biopharmaceutical industry, closed the first nine months of 2020 with significant double-digit growth rates in sales revenue and earnings. ” Businessdevelopment of the Group. Businessdevelopment of the regions.
We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. Their large revenue growth from 2021 to 2022 can be attributed to several significant businessdevelopment activities in 2022, predominantly acquisitions.
Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, which had been reported within the results of the Upjohn Business (4) in the first three quarters of 2020 , is now included within the Hospital therapeutic area for all periods presented. BNT162b2 (COVID-19 Vaccine) Development Program.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content